pubmed.ncbi.nlm.nih.gov

Interferon gamma in cancer immunotherapy - PubMed

Review

. 2018 Sep;7(9):4509-4516.

doi: 10.1002/cam4.1700. Epub 2018 Jul 23.

Affiliations

Review

Interferon gamma in cancer immunotherapy

Ling Ni et al. Cancer Med. 2018 Sep.

Abstract

Immune system can recognize self vs transformed self. That is why cancer immunotherapy achieves notable benefits in a wide variety of cancers. Recently, several papers reported that immune checkpoint blockade therapy led to upregulation of IFNγ and in turn clearance of tumor cells. In this review, we conducted an extensive literature search of recent 5-year studies about the roles of IFNγ signaling in both tumor immune surveillance and immune evasion. In addition to well-known functions, IFNγ signaling also induces tumor ischemia and homeostasis program, resulting in tumor clearance and tumor escape, respectively. The yin and the yang of IFNγ signaling are summarized. Thus, this review helps us to comprehensively understand the roles of IFNγ in tumor immunity, which contributes to better design and management of clinical immunotherapy approaches.

Keywords: IFNγ signaling; cancer immunotherapy; immune evasion; immune surveillance; transformed self.

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

PubMed Disclaimer

Figures

Figure 1
Figure 1

The roles of IFNγ signaling in tumor clearance. IFNγ signaling activates STAT1. Phosphorylated STAT1 binds to specific promoter elements and modulate transcription of IFNγ‐regulated genes. The positive consequences of IFNγ ligation consist of increased efficacy of radiotherapy, induction of tumor cell apoptosis and necroptosis, generation of ischemia, activation of APCs, promotion of Treg cell fragility, inhibition of gMDSC function and switch M2 from TAMs

Figure 2
Figure 2

The roles of IFNγ signaling in tumor escape. IFNγ signaling induces tumor cells to express tolerant molecules, such as PD‐L1, which functions as a molecular shield to protect PD‐L1+ tumor cells from immune attack, while downregulates TNFSF15 to promote angiogenesis. In addition, IFNγ signaling induces Muc16 expression and homeostasis program to promote tumor progression

Figure 3
Figure 3

The yin and the yang of IFNγ signaling in cancer immunity. IFNγ plays a dual and opposing role in cancer development. IFNγ signaling inhibits tumor growth by arrest of tumor cell cycle, induction of tumor ischemia and activation of APCs and effector cells while impairing suppressive immune cells. Meantime, IFNγ contributes to tumor growth via promotion of tumorigenesis and angiogenesis, upregulation of tolerant molecules and induction of homeostasis program

Similar articles

Cited by

References

    1. Tian T, Olson S, Whitacre JM, Harding A. The origins of cancer robustness and evolvability. Integr Biol (Camb). 2011;3:17‐30. - PubMed
    1. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836‐848. - PubMed
    1. Chen H, Liakou CI, Kamat A, et al. Anti‐CTLA‐4 therapy results in higher CD4+ICOShi T cell frequency and IFN‐gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009;106:2729‐2734. - PMC - PubMed
    1. Dulos J, Carven GJ, van Boxtel SJ, et al. PD‐1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35:169‐178. - PubMed
    1. Peng W, Liu C, Xu C, et al. PD‐1 blockade enhances T‐cell migration to tumors by elevating IFN‐gamma inducible chemokines. Cancer Res. 2012;72:5209‐5218. - PMC - PubMed

Publication types

MeSH terms

Substances